# US 2020/0369725 A1 · Novel tumor-specific polypeptide and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0369725 A1
- Document ID: US20200369725A1
- Status: Published application
- Kind: A1
- Application number: 16/326,659
- Filed: 2016-08-19
- Published: 2020-11-26
- Earliest claimed: 2016-08-19
- Assignees: Genoimmune Therapeutics Co., Ltd.
- Applicants: Genoimmune Therapeutics Co., Ltd.
- Inventors: Yong HOU; Shuntao Luo; Ting An; Xiumei Lin; Bo Li; Guanglei Li
- Web page: https://patentgrep.com/patent/US20200369725A1

## CPC

- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- C07K 7/06: having 5 to 11 amino acids
- A61K 40/10: characterised by the cell type used
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4269: {NY-ESO}
- A61P 35/00: Antineoplastic agents
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- G01N 33/575: for cancer
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- A61K 2239/31: characterized by the route of administration
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a novel tumor-specific polypeptide and use thereof. In particular, the present invention relates to a tumor-specific polypeptide having high affinity for HLA-A0201 and having cytotoxic T lymphocyte inducing ability, and its use for diagnosing, preventing and treating diseases (especially cancer) associated with high expression of the TWISTNB gene or mutation(s) in the TWISTNB gene.

## Claims

### Claim 1

A polypeptide or a derivative thereof selected from the group consisting of
a) a polypeptide comprising or consisting of the amino acid sequence KLMGIVYKV as set forth in SEQ ID NO: 2; or
b) a polypeptide having an amino acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% identical to SEQ ID NO: 2, wherein said polypeptide has the ability of inducing cytotoxic T lymphocyte cells; or
c) a polypeptide having an amino acid sequence comprising at least one or several amino acid substitutions, deletions and/or additions compared to SEQ ID NO: 2, wherein said polypeptide has the ability of inducing cytotoxic T lymphocyte cells; or
d) a polypeptide derivative which is a derivative of any of a)-c), wherein the polypeptide derivative has the ability of inducing cytotoxic T lymphocyte cells.

### Claim 2 (depends on 1)

The polypeptide or derivative thereof according to claim 1, characterized in one of the following: the second amino acid from the N-terminus of the amino acid sequence of the polypeptide is substituted with leucine or methionine, and/or the amino acid at the C-terminus is substituted with valine or leucine,
the polypeptide comprises a TWISTNB protein fragment having an amino acid sequence with a substitution or addition of at least one or several amino acids compared to SEQ ID NO: 2, or a TWISTNB protein fragment comprising the polypeptide of SEQ ID NO: 2, or
the polypeptide comprises or consists of the following amino acid sequence:
(SEQ ID NO: 2)
KLMGIVYKV;
(SEQ ID NO: 3)
KMMGIVYKV;
(SEQ ID NO: 4)
KLMGIVYKL;
(SEQ ID NO: 5)
KMMGIVYKL.

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 1)

A polynucleotide encoding the polypeptide of claim 1.

### Claim at position 5

6-37. (canceled)

### Claim 38 (depends on 1)

A method of preventing or treating a disease associated with high expression of the TWISTNB gene or mutation(s) in the TWISTNB gene in a subject, the method comprising administering to the subject an effective amount of the polypeptide or derivative thereof according to claim 1.

### Claim 39 (depends on 38)

The method according to claim 38, wherein the disease is cancer.

### Claim 40 (depends on 39)

The method according to claim 39, wherein the cancer comprises breast cancer, lung cancer, nasopharyngeal cancer, liver cancer, gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, melanoma, skin cancer, prostate cancer, cervical cancer, leukemia, brain tumors.

### Claim 41 (depends on 40)

The method according to claim 40, wherein the subject is a mammal; preferably, the subject is a human.

### Claim 42 (depends on 41)

The method according to claim 41, wherein the subject's HLA antigen is an HLA-A2 subtype, preferably an HLA-A0201 subtype.

### Claim 43 (depends on 1)

An in vitro method of diagnosing a disease associated with high expression of the TWISTNB gene or mutation(s) in the TWISTNB gene in a subject, comprising the steps of:
obtaining serum from the subject; and
detecting the presence of the polypeptide or derivative thereof according to claim 1.

### Claim 44 (depends on 43)

The method according to claim 43, wherein the detecting is performed by mass spectrometry.

### Claim 45 (depends on 44)

The method according to claim 44, wherein the disease is cancer.

### Claim at position 14

46-53. (canceled)
